Based on these findings, the patient was referred to a primary care physician for an evaluation of possible systemic causes of BRVO, and treatment with intraocular anti-VEGF injections was proposed. Anti-VEGF therapy was chosen to reduce macular edema and improve visual acuity, as recommended by current clinical guidelines [7,8]. The gene discussed is VEGFA; the disease is macular retinal edema.